Navigation Links
Aegera Initiates Phase 2 Clinical Trial Of AEG33773 - A Small Molecule Targeting Neuropathic Pain
Date:5/6/2009

>)

Aegera Therapeutics is a clinical stage biotechnology company focused on developing targeted therapeutics for major unmet medical needs. Aegera has three programs in clinical development. In addition to AEG33773, Aegera is developing

    - AEG35156 targets the key anti-apoptotic protein XIAP, and is in
      multiple randomized Phase II clinical trials;
    - HGS1029(AEG40826) is a small molecule pan-IAP inhibitor in Phase 1
      development. It has demonstrated very promising preclinical activity
      and is partnered with Human Genome Sciences, Inc. (Nasdaq:  HGSI) for o
      ncology in all countries except Japan.

'/>"/>
SOURCE AEGERA THERAPEUTICS INC.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Human Genome Sciences and Aegera Therapeutics Announce Licensing and Collaboration Agreement on Novel Anti-Cancer Drugs
2. Aegera initiates Phase 1 clinical trial of AEG33773 - A small molecule in development for diabetic neuropathic pain
3. Aegera Therapeutics welcomes two experienced executives to its board of directors
4. Aegera Therapeutics collaboration with Human Genome Sciences leads to the initiation of a Phase 1 clinical trial with lead IAP inhibitor HGS1029 and receipt of first milestone payment
5. Aegera Therapeutics phase 1/2 clinical trial results selected for oral presentation at 2008 ASH Annual Meeting
6. Aegera Therapeutics Initiates A Randomized Phase 2 Combination Study of AEG35156 for 1st Line Treatment of Non-Small Cell Lung Cancer
7. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
8. Dawson James Securities Initiates Research Coverage on CryoCor, Inc. (Nasdaq: CRYO) with a Strong Buy Rating and $6.00 Target Price
9. Spectrum Pharmaceuticals Initiates Second Registrational Phase 3 Clinical Trial for EOquin(R) in Patients With Non-Invasive Bladder Cancer
10. XTL Biopharmaceuticals Initiates Phase IIb Clinical Trial of Bicifadine for the Treatment of Diabetic Neuropathic Pain
11. Nventa Initiates HspE7 Phase 1 Cervical Dysplasia Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/18/2014)... DOYLESTOWN, Pa. , Nov. 18, 2014  Novira ... therapies for curative treatment of chronic hepatitis B virus ... , M.D., was appointed to its Scientific Advisory Board ... Brian join our SAB," said Christian S. Schade ... wealth of clinical development experience which will be invaluable ...
(Date:11/16/2014)... 17, 2014 The “Fluid Management ... fluid visualization systems market with an analysis and ... & irrigation, dialyzes, fluid warming and waste management. ... the fluid visualization systems by applications and regions ... market was valued at $19,285.5 million in 2013 ...
(Date:11/15/2014)... As part of an ongoing ... in its network and logistics capabilities to meet ... the complex requirements of the industry. , The ... logistics and transportation, and includes opening new QuickSTAT ... will be an emphasis on Customer Service capabilities, ...
(Date:11/15/2014)... 2014 CannLabs, Inc. ... analytics, and scientific testing methodologies relating to cannabis, ... ended September 30, 2014, and provided a business ... ,     CannLabs – Nevada, Inc. granted license for ...     CannLabs – Connecticut, Inc. opened a 4,000-sq.-ft. ...
Breaking Biology Technology:Novira Therapeutics Announces Appointment of Brian F. Daniels, M.D., to its Scientific Advisory Board 2Novira Therapeutics Announces Appointment of Brian F. Daniels, M.D., to its Scientific Advisory Board 3Fluid Visualization Systems Market poised to reach $25,908.4 Million by 2018 - New Research Report by MarketsandMarkets 2Fluid Visualization Systems Market poised to reach $25,908.4 Million by 2018 - New Research Report by MarketsandMarkets 3Fluid Visualization Systems Market poised to reach $25,908.4 Million by 2018 - New Research Report by MarketsandMarkets 4QuickSTAT Announces Global Expansion Plan to Enhance Its Global Network and Cold Chain Logistics Capabilities for Life Sciences 2CannLabs Announces Third Quarter 2014 Results. 2CannLabs Announces Third Quarter 2014 Results. 3CannLabs Announces Third Quarter 2014 Results. 4CannLabs Announces Third Quarter 2014 Results. 5
... 20, 2010 ... ... --> ... // Results are keyed by longUrl, so we need to grab the first one. for (var r in data.results) ...
... SAN DIEGO, Oct. 19, 2010 Amylin Pharmaceuticals, Inc. ... net product sales for the quarter ended September 30, ... the quarter include $132.4 million for BYETTA® (exanatide) injection ... compares to net product sales of $192.9 million consisting ...
... 19, 2010 -- The Cold Triple Axis spectrometer, a ... Isotope Reactor and a complementary tool to other neutron ... The CTAX uses "cold" neutrons from the HFIR ... Cold neutrons are slower than their "thermal" neutron counterparts, ...
Cached Biology Technology:JIPH Accepted for MEDLINE Indexing 2JIPH Accepted for MEDLINE Indexing 3JIPH Accepted for MEDLINE Indexing 4JIPH Accepted for MEDLINE Indexing 5JIPH Accepted for MEDLINE Indexing 6JIPH Accepted for MEDLINE Indexing 7JIPH Accepted for MEDLINE Indexing 8JIPH Accepted for MEDLINE Indexing 9ORNL's research reactor revamps veteran neutron scattering tool 2
(Date:11/5/2014)... his career to understanding the Earth,s climate and ... As deputy director and regional climatologist for the ... Institute, Redmond has more than three decades of ... climate data to the general public. , At ... on December 15-19, 2014 the American Geophysical Union ...
(Date:11/4/2014)... Fla. (November 4, 2014) — Think about the way ... How do neighboring cells know that they are supposed ... how do these tissues find the correct place and ... answering these crucial questions. , In a new study, ... to communicate with their surrounding neighbors, at the head-trunk ...
(Date:11/3/2014)... 2014 Research and Markets has announced ... Technologies, Markets and Companies" to their offering. ... methods, which have already started to play an important role ... replacing the old fashioned bone marrow transplants. Role of cells ... to become a part of medical practice. Stem ...
Breaking Biology News(10 mins):Nevada climatologist to be honored at AGU Fall Meeting for lifetime of public outreach 2The inside story: How the brain and skull stay together 2Global Cell Therapy - Technologies, Markets and Companies: 2014 Report 2Global Cell Therapy - Technologies, Markets and Companies: 2014 Report 3
... debated the cause of the Plague of Athens. Analysis ... collected from teeth from an ancient Greek burial pit ... this devastating epidemic. The study appears on the online ... published by Elsevier on behalf of the International Society ...
... invasive weed that has spread across much of the U.S. ... chemicals harmful to a soil fungus the trees depend on ... Public Library of Science. The tree-stifling alien, garlic mustard (Alliaria ... since spread to Canada and 30 states in the East ...
... to screen blood donations in all US states for West Nile ... view, say researchers from Columbia University and Harvard School of Public ... of year to worry about mosquitoes, it seems a good time ... products for WNV, and to ensure that the best policy is ...
Cached Biology News:Typhoid fever led to the fall of Athens 2Invasive species harms native hardwoods by killing soil fungus 2Invasive species harms native hardwoods by killing soil fungus 3Screening blood for West Nile virus 2
... Immunogen: Synthetic peptide derived from the N-terminal ... ZO-1. Specificity: Specific for the N-terminus ... Reactivity: Human Dog Rat Mouse (positive controls: ... mouse liver heart blood vessel and brain ...
Human Carnosine Dipeptidase 1 Affinity Purified PAb...
... Lauryl Ether 30% concentration ... Preservative. Surfactant. Clear Solution. ... is 1 mL of ... added to 400 mL ...
Mouse monoclonal [4i97] to HLA Class 1 A25 ( Abpromise for all tested applications). Antigen: Full length protein (Human): HLA Class 1 Antigen-A25. Swiss Protein ID: P18462...
Biology Products: